NCT04700176: A trial that was reported late by Hackensack Meridian Health
This trial has reported, although it was 63 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04700176 |
|---|---|
| Title | A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 2, 2022 |
| Completion date | Nov. 15, 2023 |
| Required reporting date | Nov. 14, 2024, midnight |
| Actual reporting date | Jan. 17, 2025 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 63 |